| pubmed-article:8619899 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8619899 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:8619899 | lifeskim:mentions | umls-concept:C0011685 | lld:lifeskim |
| pubmed-article:8619899 | lifeskim:mentions | umls-concept:C1883036 | lld:lifeskim |
| pubmed-article:8619899 | lifeskim:mentions | umls-concept:C1708096 | lld:lifeskim |
| pubmed-article:8619899 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8619899 | lifeskim:mentions | umls-concept:C1704711 | lld:lifeskim |
| pubmed-article:8619899 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8619899 | pubmed:dateCreated | 1996-6-13 | lld:pubmed |
| pubmed-article:8619899 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8619899 | pubmed:abstractText | Tricyclic antidepressant overdose can be reversed in rats by drug-specific antibody Fab fragments, but the required Fab dose may itself by toxic. We studied the potential use of a smaller, recombinant desipramine (DMI)-specific single chain Fv fragment (B9-sFv) for this purpose. Anesthetized rats received a tracer (subtoxic) dose of [3H]-DMI followed in 15 min by B9-IgG, B9-Fab, B9-sFv (0.1 mumol of binding sites) or BSA. Each of the active treatments produced a rapid and substantial increase in the serum radiolabel concentration, whereas BSA did not (P < 0.001). The increase in serum radiolabel concentration 1 min after treatment was 13.3-fold with B9-IgG, 10.0-fold with B9-Fab and 7.3-fold with B9-sFv. Serum antibody concentrations were also highest after B9-IgG and lower with B9-Fab or B9-sFv. The 24-hr urinary excretion of radiolabel did not differ among groups, but was extensive even in the BSA group and probably represented the excretion of DMI metabolites. B9-sFv concentrations in urine or buffer at 37 degrees declined by >90% over 24 hr, but this fragment was much more stable in serum, retaining 70% of its activity after 96 hr. These data demonstrate that B9-sFv can alter markedly the distribution of [3H]-DMI in vivo. The rapidity of this effect, and its magnitude in comparison with Fab fragment or IgG, suggest that further study of B9-sFv as a treatment of DMI overdose is warranted. | lld:pubmed |
| pubmed-article:8619899 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8619899 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8619899 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8619899 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8619899 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8619899 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8619899 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8619899 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8619899 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8619899 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8619899 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8619899 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8619899 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8619899 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8619899 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8619899 | pubmed:issn | 0006-2952 | lld:pubmed |
| pubmed-article:8619899 | pubmed:author | pubmed-author:RoseC SCS | lld:pubmed |
| pubmed-article:8619899 | pubmed:author | pubmed-author:FlickingerM... | lld:pubmed |
| pubmed-article:8619899 | pubmed:author | pubmed-author:LiuNN | lld:pubmed |
| pubmed-article:8619899 | pubmed:author | pubmed-author:KeylerD EDE | lld:pubmed |
| pubmed-article:8619899 | pubmed:author | pubmed-author:MurtaughM PMP | lld:pubmed |
| pubmed-article:8619899 | pubmed:author | pubmed-author:PentelP RPR | lld:pubmed |
| pubmed-article:8619899 | pubmed:author | pubmed-author:ShelverW LWL | lld:pubmed |
| pubmed-article:8619899 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8619899 | pubmed:day | 23 | lld:pubmed |
| pubmed-article:8619899 | pubmed:volume | 51 | lld:pubmed |
| pubmed-article:8619899 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8619899 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8619899 | pubmed:pagination | 531-7 | lld:pubmed |
| pubmed-article:8619899 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:meshHeading | pubmed-meshheading:8619899-... | lld:pubmed |
| pubmed-article:8619899 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8619899 | pubmed:articleTitle | Effects of recombinant drug-specific single chain antibody Fv fragment on [3H]-desipramine distribution in rats. | lld:pubmed |
| pubmed-article:8619899 | pubmed:affiliation | Department of Medicine, Hennepin County Medical Center, Minneapolis, MN 55415, USA. | lld:pubmed |
| pubmed-article:8619899 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8619899 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8619899 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:16059 | entrezgene:pubmed | pubmed-article:8619899 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8619899 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8619899 | lld:pubmed |
